These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 3210014)

  • 1. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain.
    Sofic E; Riederer P; Heinsen H; Beckmann H; Reynolds GP; Hebenstreit G; Youdim MB
    J Neural Transm; 1988; 74(3):199-205. PubMed ID: 3210014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease.
    Dexter DT; Wells FR; Lees AJ; Agid F; Agid Y; Jenner P; Marsden CD
    J Neurochem; 1989 Jun; 52(6):1830-6. PubMed ID: 2723638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains.
    Riederer P; Sofic E; Rausch WD; Schmidt B; Reynolds GP; Jellinger K; Youdim MB
    J Neurochem; 1989 Feb; 52(2):515-20. PubMed ID: 2911028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains.
    Sofic E; Paulus W; Jellinger K; Riederer P; Youdim MB
    J Neurochem; 1991 Mar; 56(3):978-82. PubMed ID: 1704426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
    Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
    Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuromelanin associated redox-active iron is increased in the substantia nigra of patients with Parkinson's disease.
    Faucheux BA; Martin ME; Beaumont C; Hauw JJ; Agid Y; Hirsch EC
    J Neurochem; 2003 Sep; 86(5):1142-8. PubMed ID: 12911622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.
    Hirsch EC; Brandel JP; Galle P; Javoy-Agid F; Agid Y
    J Neurochem; 1991 Feb; 56(2):446-51. PubMed ID: 1988548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies about iron in parkinsonian and control substantia nigra.
    Gałazka-Friedman J; Friedman A
    Acta Neurobiol Exp (Wars); 1997; 57(3):217-25. PubMed ID: 9407708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum cholesterol and nigrostriatal R2* values in Parkinson's disease.
    Du G; Lewis MM; Shaffer ML; Chen H; Yang QX; Mailman RB; Huang X
    PLoS One; 2012; 7(4):e35397. PubMed ID: 22530017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
    Dexter DT; Carayon A; Javoy-Agid F; Agid Y; Wells FR; Daniel SE; Lees AJ; Jenner P; Marsden CD
    Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders.
    Tong J; Rathitharan G; Meyer JH; Furukawa Y; Ang LC; Boileau I; Guttman M; Hornykiewicz O; Kish SJ
    Brain; 2017 Sep; 140(9):2460-2474. PubMed ID: 29050386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time-dependent changes in iron levels and associated neuronal loss within the substantia nigra following lesions within the neostriatum/globus pallidus complex.
    Sastry S; Arendash GW
    Neuroscience; 1995 Aug; 67(3):649-66. PubMed ID: 7545796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The history of the research of iron in parkinsonian substantia nigra.
    Friedman A; Galazka-Friedman J
    J Neural Transm (Vienna); 2012 Dec; 119(12):1507-10. PubMed ID: 22941506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distribution of iron in the basal ganglia and neocortex in postmortem tissue in Parkinson's disease and Alzheimer's disease.
    Griffiths PD; Crossman AR
    Dementia; 1993; 4(2):61-5. PubMed ID: 8358514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease.
    Sofic E; Lange KW; Jellinger K; Riederer P
    Neurosci Lett; 1992 Aug; 142(2):128-30. PubMed ID: 1454205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Substance P immunoreactivity in the post-mortem parkinsonian brain.
    Tenovuo O; Rinne UK; Viljanen MK
    Brain Res; 1984 Jun; 303(1):113-6. PubMed ID: 6203617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron and reactive oxygen species activity in parkinsonian substantia nigra.
    Wypijewska A; Galazka-Friedman J; Bauminger ER; Wszolek ZK; Schweitzer KJ; Dickson DW; Jaklewicz A; Elbaum D; Friedman A
    Parkinsonism Relat Disord; 2010 Jun; 16(5):329-33. PubMed ID: 20219408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complex I, iron, and ferritin in Parkinson's disease substantia nigra.
    Mann VM; Cooper JM; Daniel SE; Srai K; Jenner P; Marsden CD; Schapira AH
    Ann Neurol; 1994 Dec; 36(6):876-81. PubMed ID: 7998774
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain iron deposition in Parkinson's disease imaged using the PRIME magnetic resonance sequence.
    Graham JM; Paley MN; Grünewald RA; Hoggard N; Griffiths PD
    Brain; 2000 Dec; 123 Pt 12():2423-31. PubMed ID: 11099445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nigral iron deposition occurs across motor phenotypes of Parkinson's disease.
    Jin L; Wang J; Jin H; Fei G; Zhang Y; Chen W; Zhao L; Zhao N; Sun X; Zeng M; Zhong C
    Eur J Neurol; 2012 Jul; 19(7):969-76. PubMed ID: 22288465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.